Asahi Kasei Corp

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asahi Kasei Corp. operates as a holding company which provides monitoring, planning, and strategic management to its subsidiaries and affiliates. Its operations are carried out through the following segments: Materials, Homes, Health Care, and Others. The Materials segment includes caustic soda, chlorine, acrylonitrile, styrene, methyl methacrylate, adipic acid, polyethylene, polystyrene, and other petrochemicals. The Homes segment includes Long Life Home products and also provides remodeling, real estate, and urban redevelopment. The Health Care segment includes pharmaceuticals and diagnostic reagents. The Others segment includes engineering, employment agency and temporary staffing services. The company was founded on May 21, 1931 and is headquartered in Tokyo, Japan.

TOKYO & NOVI, Mich. & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Pharma has entered a new licensing agreement with Chiome Bioscience for its humanized anti-CX3CR1 antibody.

Asahi Kasei Pharma Strengthens Global Reach with Exclusive License Agreement for anti-CX3CR1 Antibody

DÜSSELDORF, Germany & TOKYO & NOVI, Mich.--(BUSINESS WIRE)--Jiangsu Sailboat Petrochemical (Sailboat) started commercial operation of a new carbonates plant in Lianyungang, Jiangsu Province.

Licensee of Asahi Kasei Technology Begins Commercial Production of High-Purity Carbonates Using CO2 as Main Feedstock in China

TOKYO & NOVI, Mich. & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Battery Separator Corporation broke ground on its new lithium-ion battery separator manufacturing facility in Port Colborne, Canada.

Asahi Kasei Battery Separator Corporation Breaks Ground on Lithium-ion Battery Separator Plant in the Niagara Region

Honda

TOKYO & NOVI, Mich. & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei and Honda announced they have signed a shareholders' agreement to convert an Asahi Kasei subsidiary into a joint venture company.

Asahi Kasei and Honda Sign Shareholders' Agreement to Convert Existing Asahi Kasei Subsidiary into Joint Venture for Production of Lithium-ion Battery Separators in Canada

TOKYO & NEW YORK & DÜSSELDORF--(BUSINESS WIRE)--Asahi Kasei Medical has launched the Planova™ FG1, a virus removal filter featuring higher flux for the manufacture of biotherapeutics.

Asahi Kasei Medical launches Planova™ FG1 next-generation virus removal filter

NOVI, Mich.--(BUSINESS WIRE)--Asahi Kasei America, Inc., plans to relocate its corporate office from New York to Novi, Michigan.

Asahi Kasei America, Inc. Moves Headquarters to Novi, Michigan

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei launches new grade of LASTAN™ flame-retardant nonwoven fabric.

Asahi Kasei Launches New Grade of LASTAN™ Flame-Retardant Nonwoven Fabric

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei enters collaboration with De Nora for development and sale of small-scale containerized electrolyzers for hydrogen production.

Asahi Kasei Enters Collaboration With De Nora for Development and Sale of Small-Scale Containerized Electrolyzers for Hydrogen Production

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Microdevices Corporation (AKM) opened the “AKM Co-creation & Technology Center” in Yokohama City, Kanagawa Prefecture, Japan.

Asahi Kasei establishes the “AKM Co-creation & Technology Center,” a development base to consolidate the organization's functions, in Shin-Yokohama, Japan

DÜSSELDORF, Germany & NEW YORK--(BUSINESS WIRE)--Asahi Kasei will exhibit its broad range of diversified material solutions at Fakuma 2024 from October 15-19 in Friedrichshafen, Germany.

Asahi Kasei to Showcase Material Solutions for Thermal Management of EVs, Recycling and 3D Printing at Fakuma 2024

Matmerize's powerful AI platform, PolymRize™, aids Asahi Kasei in designing sustainable, carbon-neutral polymers for electronics and energy applications.

Asahi Kasei Selects PolymRize™ to Advance Polymer Informatics for Sustainable Innovation

DÜSSELDORF, Germany & NEW YORK--(BUSINESS WIRE)--Asahi Kasei's newest global car user survey gives insights into the brand loyalty and buying behavior of car users in major automotive markets.

Wavering brand loyalty challenging car manufacturers globally – Fifth car user survey by Asahi Kasei

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei has announced that in April 2024 it began selling a membrane system to produce WFI.

Asahi Kasei Launches Membrane System to Produce Water for Injection

NEW YORK & TOKYO & DÜSSELDORF--(BUSINESS WIRE)--Crystal IS, an Asahi Kasei company, announced the successful serial production of 100 mm diameter single-crystal AlN substrates with 99% usable area.

Crystal IS and Asahi Kasei have achieved 99% usable area on 100 mm bulk aluminum nitride substrate

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Bionova Scientific will start providing services leveraging plasmid DNA, and establish a dedicated facility for this purpose in Texas, the U.S.

Bionova Scientific, U.S. biologics CDMO of the Asahi Kasei Group, to establish a facility in Texas and launch plasmid DNA business

DÜSSELDORF, Germany & TOKYO & NEW YORK--(BUSINESS WIRE)--Asahi Kasei Medical has completed the construction of its third assembly plant for Planova™ virus removal filters in Japan.

Asahi Kasei Medical completes new assembly plant for Planova™ virus removal filters

Calliditas Therapeutics AB

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Corp. (TOKYO:3407) today announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei (“the Acquisition”) through a voluntary tender offer for Calliditas (“the Tender Offer”). The Tender Offer will also include a concurrent offer by Asahi Kasei to acquire all American Depos.

Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company

Japan's Asahi Kasei said on Tuesday it offered to acquire Calliditas Therapeutics for about 11.8 billion Swedish crowns ($1.1 billion) as part of a plan to become a global drug company.

Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion

STOCKHOLM , May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (" ADS ") of Calliditas Therapeutics AB (publ) (jointly the " Securityholders ") accept the public tender offer by Asahi Kasei Corporation. Background     This statement is made by the Board of Directors (the "Board") of Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") pursuant to section II.19 of the Nasdaq Stockholm takeover rules ("Section II.19") and Regulation 14D under the Securities Exchange Act of 1934, as amended (together with Section II.19, the "Takeover Rules").

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--On May 13, Asahi Kasei, partners, and the Japanese government celebrated the official opening of a new hydrogen pilot plant in Kawasaki, Japan.

Asahi Kasei starts operation of multi-module hydrogen pilot plant in Kawasaki

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Bioprocess' (AKB) THESYS™ ACS ERGO synthesis column will be on display and demonstrated at Booth 213 at TIDES USA 2024.

Asahi Kasei Bioprocess to Unveil THESYS™ ACS ERGO Synthesis Column at TIDES USA

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei plans to construct an integrated plant in Ontario, Canada for base film manufacturing and coating of Hipore™ wet-process LIB separator.

Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Bioprocess (AKB) and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.

Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--APNA, Asaclean, and Elastomer will highlight new technologies at NPE 2024 from May 6 through 10 in Orlando, Florida.

Asahi Kasei to Highlight Sustainability, 3D Printing Filaments, Purging Compounds, and More at NPE 2024

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--AW Technologies and Asahi Kasei Medical have entered into an exclusive distribution agreement in Japan for AW Technologies' TrachFlush™ device.

News for Asahi Kasei Corp Stock (AHKSY)